Pharvaris NV, a late-stage biopharmaceutical company, has announced the upcoming presentation of clinical trial data concerning deucrictibant, an oral bradykinin B2 receptor antagonist, for the treatment of hereditary angioedema $(HAE)$. The data will be showcased at the US Hereditary Angioedema Association's 2025 National Summit, scheduled from July 10-13 in Baltimore, Maryland. The presentations will cover various aspects of deucrictibant, including its long-term safety and efficacy, its durability of response for on-demand treatment, and a comparison with standard care. These findings will be presented on July 11, 2025, during a poster session. The posters will also be accessible on Pharvaris' website.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。